AIMS Is Nothing but a Number: Focusing on Function and Family in Tardive Dyskinesia

Tardive dyskinesia management extends beyond symptom reduction to restoring function and quality of life for patients and caregivers. This session reviews neurobiology, early recognition, differential diagnosis, and assessment strategies while examining clinical and real-world evidence for VMAT2 inhibitors to help clinicians optimize long-term treatment outcomes.

Supported by educational grants from Neurocrine Biosciences, Inc and Teva Pharmaceuticals.